News

New technology can potentially overcome CAR T-cell limitations
July 22, 2016

Dr Philip Low speaks with ecancertv at AACR 2016 about a novel technique to selectively identify tumour cells in vivo. With potentially toxic side effects to uncontrolled tumour lysis and hard-to-target heterogeneity, Dr Low describes a new method of using fluorescein dye to bridge tumours and T Cells. By controlling administration rate and relying on large tumour-ligand libraries currently available, Dr Low reports significant tumour reduction at a low cost. In adjacent human clinical trials, fluorescein dye binding to tumours has also improved tumour visibility and specificity in surgery.

Purdue pushes Life Sciences
July 22, 2016

Purdue Startup Fund is raising $10 million

Cantabio and Purdue sign agreement
July 22, 2016

Targeting DJ-1 protein will be investigated in treating Parkinson's disease with an agreement that has been signed between Purdue and Cantabio.

Purdue in Top 15 for U.S. Patents Granted
July 22, 2016

In 2015 Purdue was one of the Top 15 universities worldwide for being granted patents.

Purdue participated in the Cancer Moonshot Summit
July 22, 2016

The Purdue Center for Cancer Research hosted a local event as part of the nation wide Cancer Moonshot Summit on June 29, 2016.

Prof Low Describes Technological Advances in Immunotherapy, Potential to Target All Human Cancers
May 6, 2016

Professor Philip S. Low, Director of the Purdue Center for Drug Discovery, Ralph C. Corley Distinguished Professor of Chemistry and winner of the 2015 AACR award for Outstanding Achievement in Chemistry in Cancer Research, discusses the latest innovative research from his lab. Find out how technological advances in engineered T-cell therapy can target tumors with enhanced selectivity, sensitivity and control, for improved cancer immunotherapy.

AACR Annual Meeting 2016: Can a Universal Adaptor Overcome CAR T-cell Immunotherapy Limitations?
April 27, 2016

In a study presented at the AACR Annual Meeting 2016 on April 19, researchers engineered an organic bispecific adaptor molecule that can serve as a bridge between a chimeric antigen receptor (CAR) T cell and a cancer cell, and, using animal models, demonstrated how this adaptor can potentially overcome some of the limitations posed by CAR T-cell immunotherapy technologies.

Purdue research may expand engineered T-cell cancer treatment
April 22, 2016

Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."

Research Could Expand Engineered T-Cell Cancer Treatment
April 21, 2016

Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."

Purdue research may expand engineered T-cell cancer treatment
April 20, 2016

Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."